CN115768429B - 用于治疗炎症性肠病的5-氯-4-羟基-1-甲基-2-氧代-n-苯基-喹啉-3-甲酰胺钾盐 - Google Patents

用于治疗炎症性肠病的5-氯-4-羟基-1-甲基-2-氧代-n-苯基-喹啉-3-甲酰胺钾盐 Download PDF

Info

Publication number
CN115768429B
CN115768429B CN202180044567.7A CN202180044567A CN115768429B CN 115768429 B CN115768429 B CN 115768429B CN 202180044567 A CN202180044567 A CN 202180044567A CN 115768429 B CN115768429 B CN 115768429B
Authority
CN
China
Prior art keywords
compound
oxo
quinoline
chloro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180044567.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115768429A (zh
Inventor
M·H·约翰森
D·M·克罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aquilion Ltd
Original Assignee
Aquilion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquilion Ltd filed Critical Aquilion Ltd
Publication of CN115768429A publication Critical patent/CN115768429A/zh
Application granted granted Critical
Publication of CN115768429B publication Critical patent/CN115768429B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180044567.7A 2020-04-30 2021-04-30 用于治疗炎症性肠病的5-氯-4-羟基-1-甲基-2-氧代-n-苯基-喹啉-3-甲酰胺钾盐 Active CN115768429B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2006390.5 2020-04-30
GBGB2006390.5A GB202006390D0 (en) 2020-04-30 2020-04-30 Novel treatments
PCT/EP2021/061464 WO2021219881A1 (en) 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases

Publications (2)

Publication Number Publication Date
CN115768429A CN115768429A (zh) 2023-03-07
CN115768429B true CN115768429B (zh) 2024-02-09

Family

ID=71080611

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180044567.7A Active CN115768429B (zh) 2020-04-30 2021-04-30 用于治疗炎症性肠病的5-氯-4-羟基-1-甲基-2-氧代-n-苯基-喹啉-3-甲酰胺钾盐
CN202180043624.XA Pending CN115916200A (zh) 2020-04-30 2021-04-30 炎症性肠病的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180043624.XA Pending CN115916200A (zh) 2020-04-30 2021-04-30 炎症性肠病的治疗

Country Status (9)

Country Link
US (2) US20230167064A1 (https=)
EP (2) EP4142725A1 (https=)
JP (2) JP7702427B2 (https=)
KR (2) KR20230018386A (https=)
CN (2) CN115768429B (https=)
AU (2) AU2021262514A1 (https=)
CA (2) CA3177000A1 (https=)
GB (2) GB202006390D0 (https=)
WO (2) WO2021219881A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
CN115836056A (zh) * 2020-05-21 2023-03-21 Stemsynergy疗法有限责任公司 Notch抑制剂及其用途
CN115120727B (zh) * 2022-06-16 2024-02-23 甘肃农业大学 S100a9抑制剂在制备防治c型产气荚膜梭菌感染性腹泻药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024195A1 (en) * 1994-03-10 1995-09-14 Pharmacia & Upjohn Ab New use of quinoline-3-carboxamide compounds
CN102480960A (zh) * 2009-07-30 2012-05-30 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
CN102984939A (zh) * 2010-07-09 2013-03-20 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
CN103153959A (zh) * 2010-10-14 2013-06-12 伊姆纳尔公司 作为AhR活化剂的1，2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
ES2393814T3 (es) * 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
EP2590653A4 (en) * 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024195A1 (en) * 1994-03-10 1995-09-14 Pharmacia & Upjohn Ab New use of quinoline-3-carboxamide compounds
CN102480960A (zh) * 2009-07-30 2012-05-30 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
CN102984939A (zh) * 2010-07-09 2013-03-20 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
CN103153959A (zh) * 2010-10-14 2013-06-12 伊姆纳尔公司 作为AhR活化剂的1，2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Colon Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease";Milad Reda Qelliny et al.;《J. Adv. Biomed. & Pharm. Sci.》;第2卷(第4期);164-184 *
"In vitro toxicity and in silico docking analysis of two novel selective AHreceptor modulators";Selma Mahiout，et al.;《Toxicology in Vitro》;第52卷;178-179 *

Also Published As

Publication number Publication date
WO2021219881A1 (en) 2021-11-04
CA3176994A1 (en) 2021-11-04
GB202006390D0 (en) 2020-06-17
CN115768429A (zh) 2023-03-07
AU2021262514A1 (en) 2023-01-05
JP2023524518A (ja) 2023-06-12
GB2605894A (en) 2022-10-19
CN115916200A (zh) 2023-04-04
JP7702427B2 (ja) 2025-07-03
CA3177000A1 (en) 2021-11-04
WO2021219879A1 (en) 2021-11-04
EP4142724A1 (en) 2023-03-08
US20230167064A1 (en) 2023-06-01
GB2605894B (en) 2023-06-14
KR20230024892A (ko) 2023-02-21
GB202207709D0 (en) 2022-07-06
KR20230018386A (ko) 2023-02-07
EP4142725A1 (en) 2023-03-08
AU2021266154A1 (en) 2023-01-05
US20230202982A1 (en) 2023-06-29
JP2023524519A (ja) 2023-06-12

Similar Documents

Publication Publication Date Title
CN115768429B (zh) 用于治疗炎症性肠病的5-氯-4-羟基-1-甲基-2-氧代-n-苯基-喹啉-3-甲酰胺钾盐
CN111494395B (zh) 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
US12018025B2 (en) Integrin inhibitor and uses thereof
EP3183253B1 (en) Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid
CN102325778A (zh) 盐酸纳美芬二水合物
CN116768856A (zh) 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
JPS5989671A (ja) ２，５−ピペラジンジオン誘導体
CN104628708A (zh) 一种阿伐那非的晶型及其制备方法、用途和药物组合物
US12048689B2 (en) Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4
US20230303542A1 (en) Solid forms of a parp14 inhibitor
WO2018024236A1 (zh) 一种jak1选择性抑制剂的新晶型及其制备方法和用途
CN106928218A (zh) 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
CN113166168A (zh) 噻吩并吡啶酮衍生物的一水合钾盐及其制备方法
CN102770416B (zh) 美他沙酮共晶体
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
CN101111495B (zh) 晶体1h-咪唑并[4,5-b]吡啶-5-胺，7-[5-[(环己基甲基氨基)-甲基]-1h-吲哚-2-基]-2-甲基，硫酸盐(1:1)，三水合物及其药物用途
WO2025020171A1 (en) Crystalline forms of a jak/syk inhibitor
TW202510870A (zh) Jak/syk抑制劑之組合物及固體形式
AU2024320769A1 (en) Crystal form vi of acrylamide compound, and preparation method therefor and use thereof
CN117412748A (zh) 用于治疗jak介导的病症的洛普昔替尼
HK40056406B (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant